The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.
 
Jean-Luc Van Laethem
No Relationships to Disclose
 
Ivan Borbath
No Relationships to Disclose
 
Mark Karwal
Consulting or Advisory Role - Eisai
Research Funding - Eisai; Genentech; Merck Sharp & Dohme
 
Chris Verslype
Consulting or Advisory Role - Bayer; Ipsen; Novartis
Speakers' Bureau - BAYER
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; Ipsen
 
Hans Van Vlierberghe
Consulting or Advisory Role - Abbvie; Bayer; Gilead Sciences; Merck; Roche
Speakers' Bureau - Abbvie; Bayer; Gilead Sciences; Roche
Research Funding - Abbvie; Bayer; Falk Pharma; Gilead Sciences; Merck
Travel, Accommodations, Expenses - Gilead Sciences
 
Adel Kardosh
Consulting or Advisory Role - Exelixis; Exelixis
 
Vittorina Zagonel
Consulting or Advisory Role - BMS Brazil; Merck
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; BMS Brazil; Lilly; Roche; SERVIER
Travel, Accommodations, Expenses - Bayer; Roche; SERVIER
 
Per Stal
No Relationships to Disclose
 
Debashis Sarker
Honoraria - Bayer; Ipsen; Pfizer (I)
Consulting or Advisory Role - Bayer; Eisai; Eisai (I); Ipsen (I); Novartis; Surface Oncology
Speakers' Bureau - AstraZeneca; Eisai; MSD Oncology
Travel, Accommodations, Expenses - Eisai; ipsen; MiNA Therapeutics
 
Daniel H. Palmer
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; MSD; Nucana; Roche; Sirtex Medical
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Sirtex Medical
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Beigene (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Stéphane Cattan
Leadership - AstraZeneca; Ipsen; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Ipsen; Roche
 
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Ono Pharmaceutical; Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; IQVIA; MSD; Novartis; Ono Pharmaceutical
 
Sadahisa Ogasawara
Honoraria - Bayer; Eisai; Lilly; Merck
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Eisai; Lilly; Merck
Research Funding - Bayer; Eisai; Lilly
 
Abby B. Siegel
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Michael Jon Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Anran Wang
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)